The goal of this study was to address this gap through exploring the following: (1) whether the plasma levels or activity of oxidative stress-related markers, including SOD, CAT, GPx, and MDA were altered in different BMI groups of schizophrenia patients; (2) whether the differences of clinical symptoms and lipid profiles were observed in different BMI groups of patients; (3) whether there were relationships between oxidative stress, obesity, and clinical symptoms in this population. Here, SOD1 is linked to schizophrenia.